Skip to main content
. 2017 Sep 27;8(50):88008–88020. doi: 10.18632/oncotarget.21330

Figure 6. The effects of emodin and rhein on energy homeostasis of tumor-carrying athymic mice.

Figure 6

MiaPaCa2 cells grew subcutaneously in athymic mice for 8 weeks. In the last 4 weeks, the mice were treated with emodin (E, n=10), rhein (R, n=10), or vehicle (V, n=10), respectively. A group of normal athymic mice (N, n=5) were also included. When Western-blotting data are shown in A, C and F, the upper parts are representative blotting, and the lower histograms show data for all mice. (A). Hepatic glucose-6-phosphatase (G6P) and pyruvate carboxylase (PCB) were determined by Western blot. (B). Glycogen contents were determined in the liver. (C). Atrogin-1 and insulin-like growth factor binding protein-3 (IGFBP) were determined in skeletal muscle by Western blots. (D). IGF-1 was determined in skeletal muscle, and the results were normalized with the weight of samples. (E). Subcutaneous and epididymal fat pads were weighed. (F). Adipose triglyceride lipase (ATGL) was determined in subcutaneous and epididymal fat by Western blot. (G). Plasma glucose and triglycerides were determined. (H). The upper part: Body weight in three groups of tumor carriers. The arrow indicates when cancer cells were implanted. The lower part: Net difference in body weight over 8 weeks. *P<0.05 and **P<0.01; NS, not significant.